Inventor · disambiguated record
Yingda Ye
Also filed as: YE YINGDA
11 granted patents·2 pending applications·88 citations·filing 2016–2025
89Inventor score
Files withINCYTE CORP13
Top patents by PatentIndex Score
13 records- 0197US9708318B2Bicyclic heterocycles as FGFR4 inhibitorsINCYTE CORP·Filed 2016·Granted Jul 18, 2017·44 cites·41 claims
- 0294US11713317B2Tricyclic heterocyclic compounds as sting activatorsINCYTE CORP·Filed 2021·Granted Aug 1, 2023·3 cites·39 claims
- 0394US10053465B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2016·Granted Aug 21, 2018·16 cites·37 claims
- 0493US11912722B2Tricyclic heteroaryl compounds as sting activatorsINCYTE CORP·Filed 2021·Granted Feb 27, 2024·2 cites·29 claims
- 0593US11851426B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Dec 26, 2023·3 cites·20 claims
- 0693US11136326B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2019·Granted Oct 5, 2021·6 cites·31 claims
- 0791US11008344B2Tricyclic heteroaryl compounds as STING activatorsINCYTE CORP·Filed 2019·Granted May 18, 2021·5 cites·41 claims
- 0890US10947227B2Tricyclic heterocyclic compounds as sting activatorsINCYTE CORP·Filed 2019·Granted Mar 16, 2021·5 cites·35 claims
- 0986US10519163B2Pyrrolopyrimidine derivatives as TAM inhibitorsINCYTE CORP·Filed 2018·Granted Dec 31, 2019·4 cites·38 claims
- 1079US12466828B2Bicyclic amines as CDK2 inhibitorsINCYTE CORP·Filed 2023·Granted Nov 11, 2025·0 cites·47 claims
- 1176US2025325660A1Immunomodulator compounds and methods of useINCYTE CORP·Filed 2025·Application pending·0 cites
- 1264US2020397893A1Immunomodulator compounds and methods of useINCYTE CORP·Filed 2020·Application pending·0 cites
- 1338US10723705B2Heterocyclic compounds and uses thereofINCYTE CORP·Filed 2016·Granted Jul 28, 2020·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Yingda Ye files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →